A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
Status:
Completed
Trial end date:
2021-06-29
Target enrollment:
Participant gender:
Summary
The primary study objective is to determine if microdoses of ABY-029 lead to detectable
signals in sampled tissues with an EGFR pathology score ≥ 1 based on histological staining.
The secondary study objective is to assess diagnostic accuracy of ABY-029 detection by iFI
and intraoperative probe relative to histopathology diagnosis, and other indicators (e.g.
proliferation, infiltration, etc.) as the gold standard, and to measure the molecular uptake
and concentration of ABY-029 in resected specimens.